We innovate at the exciting intersection of biology, engineering and advanced computation… to deliver breakthrough products and services with world-changing significance. Ours is a comprehensive approach founded on three core capabilities – Biostrategy, Biomeasurement and Biomanufacture.
Biostrategy, Biomeasurement and Biomanufacture
Getting to market as the world transforms
Now more than ever, your route to market must navigate a complex, shifting global landscape. As risks arise, so do the potential rewards. Bioinnovation has the rare capacity to provide clarity and momentum in critical areas of opportunity, such as healthcare, agriculture and climate change.
Ideas are the easier part; making them a reality is harder. The truth is, you require more than good technology to deliver positive change in a commercial context. To get to market, you need robust, realistic strategies. We can help you develop them because we understand the tools (biotechnology), the rules (governance models) and the interests (economic models) involved. Aligning all three is the secret to business success in Bioinnovation.
Gaining insight with better information
Bioinnovation relies absolutely on Biomeasurement. It is the bedrock that enables control and optimization. But biological systems are extremely complex, span a huge scale range from km to nm and are incredibly difficult to measure. Success relies on seamless integration across numerous disciplines at which we are adept – including wetware, hardware and software.
Our unique blend of abilities helps you bring new measurement and diagnosis products to market or integrate new measurement tools into your process and catalyze productivity gains. We understand and develop innovative sensors and cutting-edge data analysis. We’re able to bring together molecular biology, assay development, physics, electronics and AI to achieve the most complex measurements. And we package them for you in robust, easy-to-use, cost-effective solutions that comply with stringent regulatory requirements, including cGMP and medical device quality systems.
Scaling up and delivering at viable cost
Researchers are continually discovering new ways to apply biology in their pursuit of breakthrough innovation. The real challenge is moving complex processes from the lab to high-volume manufacture at a cost that delivers business viability. Experience tells us that successful scale up demands optimization and invention across all disciplines – including biology, hardware, usability and control systems – plus rigorous regulatory compliance.
We can help you optimize processes and develop the custom equipment you need to deliver at commercial cost and scale. We work seamlessly across biology, process optimization and equipment design to enable the successful manufacture and delivery of your product or advanced medical therapy.
Talk to us about world-changing science
Proven in biodesign
Our proven biodesign capability has grown organically from our long history in healthcare and life sciences. Few if any of our peers can match our holistic approach which adds biodesign to the complementary disciplines of engineering and computation. This unique breadth of expertise offers significant advantages that speed and ease your path to biomanufacture.
Antha is a programming language for biology. It describes and executes complex workflows, driving massive productivity gains during biodesign. We are long-term partners with Synthace and use Antha in our labs. We can help you discover the power of Antha to unlock your science and gather the data you need without limits.
Meet the core team
"Bioinnovation has the potential to reshape the global economy and transform every sector, in profound ways. Working here in Boston with our ambitious clients to realize their ideas and discoveries is tremendously rewarding."
"Biology knows no bounds and follows different rules to typical engineering tools and materials."
"Providing unique solutions that take advantage of the breadth and depth of our collective knowledge is immensely fulfilling. I am very excited to be a part of our Boston-based bioinnovation team that expands our local and global expertise to include mammalian cell biology. This positions us to meet the diverse challenges our clients face in the ever-growing space where biological needs intersect with the computational and engineering arenas."
“What excites me most is that bioinnovation will affect so many different industries – from the obvious ones like healthcare and agriculture to the more surprising like data storage and plastics.” James Hallinan
"Our clients are diverse, the science they are trying to deliver is novel. Every project brings the opportunity to gain a new understanding."
Tech, tools & facilities
Synthetic biology labs
Located in our Cambridge head office, our microbiology lab enables us to genetically modify micro-organisms and characterise them. Our facilities are containment level 2 rated for handling pathogenic strains and our in-house libraries allow rapid modular DNA construct design and assembly. We are particularly interested in building organisms that are biological sensors for healthcare and industrial biotech applications.
Life science labs
Our suite of restricted Class II laboratories are specifically designed for handling and experimentation of pharmaceuticals, licensed substances, biological hazards and human samples in a controlled and regulated environment. Our instrumentation rooms are equipped with metrology, microscopy and product test equipment for rigorous verification and quality assurance of prototypes and products.
Cell culture labs
Our life science and synthetic biology facilities are complemented by our recently established cell culture labs. They support our clients in the advanced therapies and medicinal products field to deliver the most advanced drugs on the planet. We’ve equipped them with tools to monitor, grow and store cells which are relevant to cell and gene therapy process development.
A scalable, fully automated system for cell and gene therapy monitoring
A major milestone, enabled by our breakthrough sensing technology.
Enabling the world's first DNA-based platform for massive data storage
Harnessing the science of synthetic biology and best-in-class automation to turn organic waste into high-protein fish food.
News & insights
Cambridge Consultants announces its collaboration with MedTech Innovator, a world-leading non-profit start-up accelerator
Cambridge Consultants part of Capgemini, today announced its collaboration with MedTech Innovator Asia Pacific, the world’s leading non-profit accelerator of medical devices
Scale-down models have become an increasingly common development tool, especially in the bioprocessing industry. Read our eBook to discover our approach to the challenge of scaling up scale down models.
Cambridge Consultants & Kytopen announce the initial release of the Flowfect™ Tx System, a breakthrough that will help deliver the full promise of cell therapies to tackle disease.
Synthetic biology remains nascent, yet full of promise. The idea of using rational engineering approaches to design biology has the potential to solve some of humanity’s biggest challenges, such as securing food supplies...
- Innovation management
- Product realisation
- Strategic advice
Join us in San Francisco for the first time in three years. Growers, agribusiness leaders, technology pioneers and investors come together to exchange insights, be inspired, and identify future partners.
Join us live in London on May 4-5, 2022 for two days of intelligent debate and targeted networking with business leaders from across the value chain.
The race to bring the promise of advanced therapies to Japanese patients
At Synbiobeta 2022 see how synthetic biology is disrupting consumer products, food, agriculture, medicine, chemicals, materials, and more. The Synbiobeta Global Synthetic Biology Conference 2022 unites the leading biological engineers, investors, innovators, and entrepreneurs who make up this fast-growing industry.
Cambridge Consultants James Hallinan, head of business development for bioinnovation will be hosting a panel discussing making advanced therapies affordable to all.